ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ACS Report Says Drop in Cancer Mortality Saved 898,000 Lives Over 17 Years

June 17, 2011

CMS Inserts Unprecedented Conditions Into Medicare Coverage of Lung Screening

November 14, 2014

Breast Cancer: Pitt “Regrets” Any Harm, Expresses Pride In Fisher’s Work

September 5, 1997

NCI Cooperative Group, Cancer Center Trials Listed

February 29, 2008

In Brief: NCI Sent 82 Staff Members to Florence, 75 Of Whom Were Supported By ACS-NAS Pool

November 8, 1974

NCI To Fund Two Construction Grants With 42 Million From Special NIH Fund

March 2, 1990